Evaluation of Atorvastatin for the Treatment of Patients With Asthma: A Double-Blind Randomized Clinical Trial.
10.4168/aair.2012.4.5.290
- Author:
Abdollatif MOINI
1
;
Ghasem AZIMI
;
Abdolhay FARIVAR
Author Information
1. Department of Internal Medicine, Amir-al-Momenin Hospital, Arak University of Medical Sciences, Arak, Iran. Dr.moini@arakmu.ac.ir
- Publication Type:Clinical Trial ; Randomized Controlled Trial ; Original Article
- Keywords:
Asthma;
statins;
atorvastatin;
Asthma Control Test
- MeSH:
Asthma;
Cholesterol;
Eosinophils;
Forced Expiratory Volume;
Heptanoic Acids;
Humans;
Lipoproteins;
Lung;
Pyrroles;
Vital Capacity;
Atorvastatin Calcium
- From:Allergy, Asthma & Immunology Research
2012;4(5):290-294
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Statins are known as cholesterol-lowering agents, but have been suggested for the treatment of asthma because of their anti-inflammatory effects. In this study, the potential therapeutic effects of atorvastatin were investigated in asthmatic patients. METHODS: A total of 62 patients with persistent mild to moderate asthma who presented at asthma clinics of Arak University of Medical Sciences were recruited in a double-blind randomized clinical trial. The asthma clinical control score was assessed based on the standardized Asthma Control Test. Lung volume, i.e., percentage of forced expiratory volume in one second (FEV1%) and percentage of forced vital capacity (FVC%), and peripheral blood eosinophils were also measured. The intervention group was treated with atorvastatin 40 mg per day for 8 weeks, while the control group received a placebo. Asthma controller treatments were not changed. At the beginning and end of the study, serum cholesterol and triglyceride levels were measured to evaluate adherence of the patients to the treatment. RESULTS: The asthma control score did not significantly differ between the intervention and control groups (P=0.06). Difference in FEV1%, FVC%, and blood eosinophil count between the intervention and control groups were not statistically significant (P>0.05). The differences in post-treatment cholesterol and low-density lipoprotein cholesterol levels were significant (P<0.05). CONCLUSIONS: Our study shows that atorvastatin is not effective in the treatment of persistent mild to moderate asthma.
